Which company produces Avonib?

Ivosidenib (Ivosidenib) is developed and produced by Servier Pharmaceuticals (Servier), a company dedicated to finding solutions to today's challenges. The company's oncology portfolio includes innovative medicines designed to bring more life-saving treatments to more patients, across the disease spectrum and across tumor types.

Approved as monotherapy in the United StatesAdult patients with IDH1-mutated relapsed or refractory acute myeloid leukemia (AML) and ≥75 years of age or It can be used in combination with azacitidine to treat newly diagnosed IDH1-mutant AML patients with comorbidities that preclude the use of intensive induction chemotherapy or patients with comorbidities that preclude the use of intensive induction chemotherapy. Avosidenib is approved for the first time in non-hematological malignancies for patients who have been previously treated for IDH1-mutated cholangiocarcinoma. In addition to its favorable safety profile, ivosidenib is the first therapy to target cancer metabolism and demonstrated impressive and significant benefits of the combination in terms of event-free survival and overall survival.

The original version of ivonib has been launched in China, but it is not covered by medical insurance. The price of domestically sold specifications0.25g*60 tablets per box is as high as 100,000 yuan, while the price of the original American version sold overseas is as high as more than 200,000 yuan per box (the price may fluctuate due to exchange rates). Generic drugs of Ivonib are also sold overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 250mg*60 tablets produced by a Laos pharmaceutical factory may be more than 6,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.